Cushing’s Syndrome Treatment Research Highlights: ENDO 2024
Released On
September 30, 2024
Expires On
September 29, 2025
Media Type
Internet
Completion Time
30 minutes
Specialty
Endocrinology, Primary Care, Radiology, Surgery
Topics
Radiology
This activity is jointly provided by AffinityCE, Inc. and CheckRare CE.
This activity is supported by an independent educational grant from Recordati Rare Diseases Inc. and Xeris Pharmaceuticals.
Credit Available
- Physicians - maximum of 0.50 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in endorcrinology, radiology, neurosurgery, and general practice. Other members of the care team may also participate.
Program Overview
This 30-minute CME program highlights the latest clinical research about Cushing’s syndrome and Cushing’ disease.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage individuals with Cushing’s syndrome and its clinical relevance
- Share new information with their clinical team
Faculty
Maria Fleseriu, MD, FACE
Professor of Medicine and Neurological Surgery
Director of Pituitary Center,
Oregon Health & Science University,
Portland, Oregon
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and CheckRare CE. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
AffinityCE and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose.
Faculty Educators
Dr. Fleseriu discloses the following relevant financial relationships with ineligible companies to disclose:
- Funding to the University as Principle Investigator from Sparrow Pharmaceuticals
- Scientific consultant for Crinetics Pharmaceuticals, Recordati Rare Diseases, Sparrow Pharmaceuticals, and Xeris Pharmaceuticals
Instructions for Participation and Credit
TThere are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the post-test (achieving a passing score of 70%) and the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
American Academy of CME, Inc. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will review off-label or investigational information.
Disclaimer
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the AffinityCE or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Contact Information
For CME questions please contact: [email protected].